Blogs

The somewhat-awkwardly named TransCelerate BioPharma immediately got an enthusiastic reception from industry watchers and participants, mainly due to the perception that it was well poised to attack some of the systemic causes of delays and cost overruns that plague clinical trials today.

An entire section of Horizon 2020 is devoted to health, demographic change, and well-being.

Clinical trials community reacts favorably to tentative set of new rules, yet questions remain.

Proposed rule changes on public information in Europe never make it to fruition.